JACOBS LEVY EQUITY MANAGEMENT, INC - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 240 filers reported holding NEKTAR THERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$2,921,266
+4.3%
4,904,745
+0.7%
0.02%
+6.2%
Q2 2023$2,801,499
+52.2%
4,870,478
+86.0%
0.02%
+45.5%
Q1 2023$1,840,253
-68.3%
2,618,087
+1.8%
0.01%
-71.8%
Q4 2022$5,810,119
+75.0%
2,570,849
+147.7%
0.04%
+50.0%
Q3 2022$3,321,000
+283.5%
1,037,929
+355.3%
0.03%
+271.4%
Q2 2022$866,000
-31.0%
227,963
+145.3%
0.01%
-12.5%
Q4 2021$1,255,000
-19.8%
92,917
+6.7%
0.01%
-27.3%
Q3 2021$1,564,000
+257.9%
87,082
+241.8%
0.01%
+266.7%
Q2 2021$437,000
+11.5%
25,481
+30.0%
0.00%0.0%
Q1 2021$392,000
-69.4%
19,607
-74.0%
0.00%
-72.7%
Q4 2020$1,283,000
+0.7%
75,476
-1.7%
0.01%
-15.4%
Q3 2020$1,274,000
-6.0%
76,781
+31.2%
0.01%
-13.3%
Q2 2020$1,355,000
+731.3%
58,525
+392.6%
0.02%
+400.0%
Q1 2016$163,000
-95.3%
11,880
-95.7%
0.00%
-95.5%
Q2 2015$3,487,000
+197.0%
278,740
+161.1%
0.07%
+230.0%
Q1 2015$1,174,000
-84.5%
106,750
-78.2%
0.02%
-84.6%
Q4 2014$7,585,000
+73.7%
489,386
+35.3%
0.13%
+78.1%
Q3 2014$4,367,000
+16.1%
361,786
+23.3%
0.07%
+17.7%
Q2 2014$3,761,000
+293.4%
293,386
+248.4%
0.06%
+342.9%
Q4 2013$956,000
-11.5%
84,210
-18.5%
0.01%
-22.2%
Q3 2013$1,080,000103,3800.02%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q3 2021
NameSharesValueWeighting ↓
Camber Capital Management LP 2,000,000$67,200,0003.35%
First Light Asset Management, LLC 763,403$25,650,0003.33%
BRIDGER MANAGEMENT, LLC 1,238,489$41,613,0003.29%
Rhenman & Partners Asset Management AB 734,445$24,677,0002.89%
BB BIOTECH AG 2,020,676$67,895,0001.71%
Gs Investments, Inc. 54,200$1,821,120,0001.43%
Artal Group S.A. 900,000$30,240,0001.24%
Cormorant Asset Management, LP 500,000$16,800,0001.14%
TOBAM 640,547$21,522,0001.09%
Bellevue Group AG 430,026$14,449,0000.80%
View complete list of NEKTAR THERAPEUTICS shareholders